Granules India

Granules India gets US regulator FDA's approval for generic ADHD drug

Drug firm Granules India on Tuesday said its subsidiary has received approval from the US health regulator for a generic medication used to treat attention-deficit hyperactivity disorder. Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets, the drug firm said in a statement. The approved drug is available in multiple strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, it added. The company's product is the generic equivalent to Takeda Pharmaceuticals' Vyvanse chewable tablets, the company said. The medication is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged six years and older, as well as moderate to severe binge eating disorder (BED) in adults. Lisdexamfetamine dimesylate chewable tablets are currently published on the FDA Drug Shortages List, emphasising ..

Granules India share tanks 10% after USFDA's 'OAI' tag for Gagillapur Unit

The fall in Granules India share price came after the company announced that United States Food and Drug Administration (USFDA) has classified the inspection of Gagillapur unit as OAI

Chandan Taparia of MOFSL recommends buying these three stocks today

Wipro has broken out of a consolidation zone with a volume spike visible on the daily chart. Buying was visible across the IT Sector which may support the up move

FIIs unwind Nifty longs, add shorts in Bank Nifty; Experts see more pain

Derivatives market update for Oct 04: Data shows Balrampur Chini, Dabur, Bata India, Reliance, Axis Bank and Manappuram Finance are few of the F&O stocks that saw short build-up on Thursday.

Granules tanks 16% on concerns over 6 observations issued by US FDA

More than 31 million equity shares, representing 12.89 per cent equity of the pharmaceutical company, had changed hands on the NSE till 02:08 PM.

USFDA issues six observations for Granules' Gagillapur unit; stock falls 5%

The fall in Granules India share price came after the company announced that United States Food and Drug Administration (USFDA) has issued six observations for the company's Gagillapur facility.

F&O Cues: Options data hint more gains for Nifty; 4 stocks see long buildup

Derivative market update for Monday, Sept 02: FIIs long-short ratio in index futures rose to 2.6:1, implying 5 longs for every 2 shorts. Bandhan Bank, Syngene and Granules India see long buildup.

Ajit Mishra of Religare Broking recommends buying these stocks on August 29

PFC has registered a decisive breakout from the intermediate falling resistance trendline with strong volumes.

Apollo Tyres, Granules among top picks by Chandan Taparia of Motilal Oswal

Apollo Tyres has retested its breakout level on the daily chart with higher than average buying volumes indicating bullish sentiment

KPR Mill, eClerx: 5 midcap, smallcap stocks to play the market bounce

KPR Mill, eClerx, Granules, Cera Sanitaryware and BLS International are the 5 mid- and smallcap stocks that look strong on technical charts and can potentially gain up to 43% from present levels.

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Granules India PAT surges to Rs 135 cr in June quarter

Granules India on Tuesday said its profit after tax rose nearly three-fold year-on-year to Rs 135 crore for the first quarter ended June 30, 2024. The drug maker had reported a profit after tax (PAT) of Rs 48 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,180 crore for the period under review from Rs 985 crore in the year-ago period, the Hyderabad-based firm said in a regulatory filing. "With our robust quarterly performance, we are back on our planned trajectory after a few setbacks last year," Granules India Chairman & Managing Director Krishna Prasad Chigurupati said. The first quarter performance highlights continued growth in the formulation segment, strong North America business, and product diversification, he added. Shares of the company on Tuesday ended 4.15 per cent up at Rs 587.80 apiece on the BSE.

Promoter of Granules India sells 3.09% stake for Rs 304 cr via open market

Krishna Prasad Chigurupati, one of the promoters of Granules India, on Wednesday pared a 3.09 per cent stake in the company for Rs 304 crore through an open market transaction. According to the block deal data available on the NSE, Krishna Prasad Chigurupati offloaded 75 lakh shares, amounting to a 3.09 per cent stake in Granules India. The shares were disposed of at an average price of Rs 405.08 apiece, taking the deal size to Rs 303.81 crore, as per the data on the National Stock Exchange (NSE). According to a regulatory filing on Wednesday, Granules India said the primary objectives of the deal was to clear personal debt, to release the existing pledge on his holding in the company, and creating a small personal liquidity. "Chigurupati further notified the company that he has no plans to sell his shareholding in Granules India Ltd in the foreseeable future. "Post this transaction, the total promoter & promoter group shareholding in the company has changed from 41.96 per cent to

Granules India Q4 results: Revenue declines 1.6% on weak paracetamol sales

The company's consolidated revenue fell year-on-year to 1,176 crore rupees (nearly $141 million) for the three months to March 31

Aarti Drugs, Balrampur: 5 stocks that can surge up to 66% in Samvat 2080

Bayer Cropscience, Granules India and HLE Glasscoat are the other three stocks that can generate healthy returns till next Diwali, based on the existing chart patterns.

Granules India's Q2 revenue rises 3.4% on higher sales in North America

Its shares gained 19.5% in the September-quarter, outperforming the Nifty pharma index, which climbed 12%

Paracetamol maker Granules India flags operations hit from cyber attack

Due to significant changes in its IT systems, the IT security incident caused a major disruption in its business operations, the Paracetamol maker said in an exchange filing

Granules profit up 7.8% to Rs 120 crore boosted by drug ingredient business

Granules India reported a 7.8% rise in fourth-quarter profit, spurred by strong growth in its business of making active pharmaceutical ingredient (API) for drugs

Sensex sheds 413 pts as HDFC twins, RIL weigh; Nifty ends below 18,300

CLOSING BELL: The BSE Midcap, Smallcap indices, however, bucked the trend and ended with a gain of up to 0.2 per cent. Breadth too was marginally positive.

Indian pharma firm Granules opens packaging facility in US' Virginia

Indian pharmaceutical company Granules has opened a packaging facility in the Virginia State of the US to expand the packaging capacity of essential drugs in the state, thus strengthening the biopharma supply chain. The facility was inaugurated by India's Ambassador to the US Taranjit Singh Sandhu. Granules, which was one of the first Indian pharmaceutical companies that received FDA authorization to export to the United States, has invested more than USD 100 million in the country, said Dr Krishna Prasad Chigurupati, the founder, chairman and managing director of the firm. "We have nearly 200 employees in Virginia with a large majority of them first-generation Indians," he said, adding the company also has a team of 30 scientists for research and development. Granules India Ltd produces some of the most widely used drugs, including Paracetamol, that have been very useful to billions across the world, Chigurupati said. "Happy to see Made in India' medicines value added in the US b